News for KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferenc

JMP Securities initiates coverage on KalVista Pharmaceuticals (KALV) with Market Outperform rating and $19 price target; stock up 1.2% today.

[url=

Japan grants orphan drug status to HAE treatment

KALV Stock Touches 52-Week Low at $7.95 Amid Market Challenges

KalVista has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of 2027. Learn more on KALV stock here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

KalVista Pharmaceuticals (KALV) stock gains as Bank of America initiates coverage with a Buy rating, citing potential of its lead candidate sebetralstat. Read more here.

U.S. stock futures were slightly higher this morning, with the Nasdaq futures gaining around 0.2% points on Monday. Shares of Super Micro Computer, Inc. SMCI f...

[url="]KalVista Pharmaceuticals, Inc[/url]. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective imm

Overview of the Recent Transaction On October 1, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) made a significant new investment in the biotechnology se

Despite a lighter earnings calendar next week, several high-profile companies are set to report their financial results, which could significantly influence mar

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that...

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday.

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday.

/PRNewswire/ -- The